CEL-SCI Corporation (NYSE AMEX: CVM) reported financial results
today for the fiscal year ended September 30, 2011.
CEL-SCI’s net loss available ... read more
CEL-SCI Corporation (NYSE AMEX: CVM) provided an update today of
the progress of its Phase III clinical trial of Multikine
(Leukocyte Interleukin, Injection)*, which is currently being
... read more
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has
closed its previously announced registered direct offering for the sale
of (i) 13,333,334 shares of its common stock ... read more
CEL-SCI Corporation (NYSE AMEX: CVM) announced that its Taiwanese
partner Orient Europharma Co. Ltd. (“Orient Europharma”) today is
presenting its development strategies for CEL-SCI's investigational
... read more
CEL-SCI Corporation (NYSE AMEX: CVM) today announced that it has
entered into an exclusive Sales, Marketing and Distribution agreement
with IDC-GP Pharm LLC (“IDC-GP Pharm”) under which CEL-SCI ... read more
CEL-SCI Corporation (NYSE AMEX: CVM)
today announced that the Chinese patent office has issued a key patent
covering CEL-SCI’s investigational cancer drug, Multikine®
... read more